Dr.Christian Marsolais has over 25 years of experience in the research, development and commercialization of new drugs. He started his career in international pharmaceutical companies, including Sandoz, Biochem and Pfizer, where he held different positions from medical advisor to director clinical research and medical affairs. He was also appointed to the global oncology team at Pfizer, which managed the global oncology portfolio.
Dr. Marsolais joined Theratechnologies in 2007, and lead the medical team which was central to the approval of Egrifta by the US FDA. He was also instrumental in the efforts that lead to the US and European acquisition of the commercial rights for Trogarzo and the approval of Trogarzo by the US FDA. More recently, he also lead the team to pursue the approval of Trogarzo in Europe.
Dr. Marsolais holds a Ph.D. in biochemistry from the Université de Montréal.